Posted on December 18th, 2009 by Kelley Luckstein
Yesterday, the FDA Oncologic Drugs Advisory Committee voted 12-1 against recommending the use of erlotinib as first-line maintenance monotherapy for patients with advanced non-small cell lung cancer…
The most common adverse events with erlotinib were rash and diarrhea, according to data presented. Ronald Richardson, MD, of the division of medical oncology at the Mayo Clinic in Rochester, Minn., was one of the panelists who voted against the therapy. “We were presented with a single study that has some design flaws showing so
HemOnc Today, 12/17/09
You must be logged-in to the site to post a comment.